Literature DB >> 8506326

Molecular basis of a multiple lymphokine deficiency in a patient with severe combined immunodeficiency.

E Castigli1, R Pahwa, R A Good, R S Geha, T A Chatila.   

Abstract

We have previously reported that the T lymphocytes of a child with severe combined immunodeficiency are defective in the transcription of several lymphokine genes that include IL2, IL3, IL4, and IL5, which encode interleukins 2, 3, 4, and 5 (IL-2, -3, -4, and -5). To determine whether the defect in the patient's T lymphocytes involved a trans-acting factor common to the affected lymphokine genes, we examined the ability of nuclear factors from the patient's T lymphocytes to bind response elements present in the regulatory region of IL2. Nuclear factor NF-kB, activation protein 1 (AP-1), OCT-1, and NF-IL-2B binding activity were normal. In contrast, the binding of the nuclear factor of activated T cells (NF-AT) to its response element in the IL2 enhancer and to an NF-AT-like response element present in the IL4 enhancer was abnormal. To ascertain whether the abnormal NF-AT binding activity was related to an impaired function, we transfected patient and control T lymphocytes with constructs containing the reporter gene encoding chloramphenicol acetyl transferase (CAT) under the control of the entire IL2 regulatory region or of multimers of individual enhancer sequences. CAT expression directed by the IL2 regulatory region or by a multimer of the NF-AT-binding site was markedly lower in the patient relative to controls. In contrast, CAT gene expression directed by a multimer of the OCT-1 proximal (OCT-1p)-binding site was equivalent in patient and controls. These results indicate that an abnormality of/or influencing NF-AT may underlie the multiple lymphokine deficiency in this patient.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506326      PMCID: PMC46586          DOI: 10.1073/pnas.90.10.4728

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Primary combined immunodeficiency resulting from defective transcription of multiple T-cell lymphokine genes.

Authors:  T Chatila; E Castigli; R Pahwa; S Pahwa; N Chirmule; N Oyaizu; R A Good; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link.

Authors:  K S Ullman; J P Northrop; C L Verweij; G R Crabtree
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor.

Authors:  P Angel; M Imagawa; R Chiu; B Stein; R J Imbra; H J Rahmsdorf; C Jonat; P Herrlich; M Karin
Journal:  Cell       Date:  1987-06-19       Impact factor: 41.582

5.  The promoter of the human interleukin-2 gene contains two octamer-binding sites and is partially activated by the expression of Oct-2.

Authors:  M P Kamps; L Corcoran; J H LeBowitz; D Baltimore
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

6.  Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation.

Authors:  E A Emmel; C L Verweij; D B Durand; K M Higgins; E Lacy; G R Crabtree
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

7.  Characterization of antigen receptor response elements within the interleukin-2 enhancer.

Authors:  D B Durand; J P Shaw; M R Bush; R E Replogle; R Belagaje; G R Crabtree
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

8.  Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28.

Authors:  J D Fraser; B A Irving; G R Crabtree; A Weiss
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

9.  Nuclear events after activation of CD4+8+ thymocytes.

Authors:  J S Riegel; E R Richie; J P Allison
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

10.  The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter.

Authors:  A Granelli-Piperno; P Nolan; K Inaba; R M Steinman
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunodeficiency due to mutations in ORAI1 and STIM1.

Authors:  Stefan Feske; Capucine Picard; Alain Fischer
Journal:  Clin Immunol       Date:  2010-03-01       Impact factor: 3.969

Review 2.  Cellular and molecular basis of immunodeficiencies: their consequences for the development and induction of the immune response.

Authors:  J Sterzl
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

3.  Primary T lymphocyte immunodeficiency associated with a selective impairment of CD2, CD3, CD43 (but not CD28)-mediated signal transduction.

Authors:  C Rodríguez-Gallego; A Arnaiz-Villena; A Corell; J Manzanares; M Timón; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

Review 4.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.